Beta-Blockers for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: An Updated Meta-Analysis of Randomized Clinical Trials
Aim. Cardiotoxicity is a well-recognized complication of chemotherapy with Anthracyclines. However, results from trials evaluating beta-blockers for prevention are controversial. Therefore, we performed a meta-analysis to find whether prophylactic administration of beta-blockers can help prevent Ant...
Main Authors: | Armin Attar, Arman Karimi Behnagh, Mehrasa Hosseini, Foad Amanollahi, Paria Shafiekhani, Ali Kabir |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi-Wiley
2022-01-01
|
Series: | Cardiovascular Therapeutics |
Online Access: | http://dx.doi.org/10.1155/2022/8367444 |
Similar Items
-
Preventive use of beta-blockers for anthracycline-induced cardiotoxicity: A network meta-analysis
by: Dongsheng He, et al.
Published: (2022-08-01) -
Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials
by: Yingxu Ma, et al.
Published: (2019-04-01) -
Beta-blockers in cardiac failure.
by: Neubauer, G, et al.
Published: (1994) -
Comparative cardiac toxicity of anthracyclines in vitro and in vivo in the mouse.
by: Stefano Toldo, et al.
Published: (2013-01-01) -
Beta-blockers in cardiac arrhythmias–Clinical pharmacologist’s point of view
by: Łukasz Wołowiec, et al.
Published: (2023-01-01)